Please login to the form below

Not currently logged in
Email:
Password:

Mark Booth joins Probiodrug

He becomes chief business officer

Probiodrug Mark BoothHalle, Germany-based Probiodrug has appointed Mark Booth as its chief business officer and member of its management board.

Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

He brings over 30 years of biopharmaceutical experience to Probiodrug and has held key positions at Abbott Laboratories, Immunex Corporation and Takeda Pharmaceuticals, where he served as president of its North America operations.

Dr Erich Platzer, chairman of Probiodrug's supervisory board, said: “Mark's broad business background and proven track record make him a valuable addition to our management board.

“His extensive experience in business development and investor relations will be instrumental to propel Probiodrug's strategy internationally and in particular [in] the United States.”

Booth said: “This is truly a unique opportunity and I look forward to working with the team as we advance new and novel therapeutic treatments for Alzheimer's patients.”

31st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics